|Trade names||Droxia, Hydrea, others|
|Synonyms||Hydroxyurea (USAN US)|
|AHFS/Drugs.com||International Drug Names|
|Metabolism||liver (to CO2 and urea)|
|Biological half-life||2–4 hours|
|Excretion||Renal and lungs|
|Chemical and physical data|
|Molar mass||76.0547 g/mol|
|3D model (JSmol)|
|Melting point||133 to 136 °C (271 to 277 °F)|
Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.
Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.
Hydroxycarbamide was approved for medical use in the United States in 1967. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Hydroxycarbamide is available as a generic medication. The wholesale cost in the developing world is about 0.35 to 0.47 USD per day. In the United States it costs less than 25 USD a month.
Hydroxycarbamide is used for the following indications:
- Myeloproliferative disease (primarily polycythemia vera and essential thrombocytosis). It has been found to be superior to anagrelide for the control of ET.
- Sickle-cell disease (increases production of fetal hemoglobin that then reduces the tendency of sickle cells to sickle, as well as reducing white blood cells that contribute to the general inflammatory state in sickle cell patients.)
- Second line treatment for psoriasis (slows down the rapid division of skin cells)
- Systemic mastocytosis
- Chronic myelogenous leukemia (largely replaced by imatinib, but still in use for its cost-effectiveness)
Reported side-effects are: drowsiness, nausea, vomiting and diarrhea, constipation, mucositis, anorexia, stomatitis, bone marrow toxicity (dose-limiting toxicity; may take 7–21 days to recover after the drug has been discontinued), alopecia (hair loss), skin changes, abnormal liver enzymes, creatinine and blood urea nitrogen.
Due to its negative effect on the bone marrow, regular monitoring of the full blood count is vital, as well as early response to possible infections. In addition, renal function, uric acid and electrolytes, as well as liver enzymes, are commonly checked. Moreover, because of this, severe anemia and neutropenia are contraindicated.
Hydroxycarbamide has been used primarily for the treatment of myeloproliferative diseases, which has an inherent risk of transforming to acute myeloid leukemia. There has been a longstanding concern that hydroxycarbamide itself carries a leukemia risk, but large studies have shown that the risk is either absent or very small. Nevertheless, it has been a barrier for its wider use in patients with sickle-cell disease.
Mechanism of action
Hydroxycarbamide decreases the production of deoxyribonucleotides via inhibition of the enzyme ribonucleotide reductase by scavenging tyrosyl free radicals as they are involved in the reduction of nucleoside diphosphates (NDPs).
In the treatment of sickle-cell disease, hydroxycarbamide increases the concentration of fetal hemoglobin. The precise mechanism of action is not yet clear, but it appears that hydroxycarbamide increases nitric oxide levels, causing soluble guanylyl cyclase activation with a resultant rise in cyclic GMP, and the activation of gamma globin gene expression and subsequent gamma chain synthesis necessary for fetal hemoglobin (HbF) production (which does not polymerize and deform red blood cells like the mutated HbS, responsible for sickle cell disease). Adult red cells containing more than 1% HbF are termed F cells. These cells are progeny of a small pool of immature committed erythroid precursors (BFU-e) that retain the ability to produce HbF. Hydroxyurea also suppresses the production of granulocytes in the bone marrow which has a mild immunosuppressive effect particularly at vascular sites where sickle cells have occluded blood flow.
Brand names include: Hydrea, Litalir, Droxia, and Siklos
Hydroxyurea has been reported as endogenous in human blood plasma at concentrations of approximately 30 to 200 ng/ml.
Hydroxyurea has been prepared in many different ways since its initial synthesis in 1869. Medical chemists, Dresler and Stein created Hydroxyurea from hydroxylamine, hydrochloric acid and potassium cyanide as a technical exercise in organic chemistry, as part of a series of experiments generating derivatives of urea. Hydroxyurea lay dormant for more than fifty years until it was studied as part of an investigation into the toxicity of protein metabolites. Due to its chemical properties hydroxyurea was explored as an antisickling agent in the treatment of hematological conditions.
One common mechanism for synthesizing hydroxyurea is by the reaction of calcium cyanate with hydroxylamine nitrate in absolute ethanol and by the reaction of salt (i.e. sodium or potassium) cyanates and hydroxylamine hydrochloride in aqueous solution. Hydroxyurea has also been prepared by converting a quaternary ammonium anion exchange resin from the chloride form to the cyanate form with sodium cyanate and reacting the resin in the cyanate form with hydroxylamine hydrochloride. This method of hydroxyurea synthesis was patented by Hussain et al. (2015).
Hydroxyurea is a monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Similar to other antimetabolite anti-cancer drugs, it acts by disrupting the DNA replication process of dividing cancer cells in the body. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair.
Biochemical research has explored its role as a DNA replication inhibitor which causes deoxyribonucleotide depletion and results in DNA double strand breaks near replication forks (see DNA repair). Repair of DNA damaged by chemicals or irradiation is also inhibited by hydroxyurea, offering potential synergy between hydroxyurea and radiation or alkylating agents.
- Antineoplastic Agents – Substances that inhibit or prevent the proliferation of neoplasms.
- Antisickling Agents – Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions.
- Nucleic Acid Synthesis Inhibitors – Compounds that inhibit cell production of DNA or RNA.
- Enzyme Inhibitors – Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
- Cytochrome P-450 CYP2D6 Inhibitors – Acts as an inhibitor to one of the most important enzymes involved in the metabolism of xenobiotics in the body, CYP2D6 a member of the cytochrome P450 mixed oxidase system.
- "Hydroxyurea". The American Society of Health-System Pharmacists. Retrieved 8 December 2016.
- "Hydrea 500 mg Hard Capsules – Summary of Product Characteristics (SPC) – (eMC)". www.medicines.org.uk. Archived from the original on 20 December 2016. Retrieved 14 December 2016.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "Hydroxycarbamide". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 295. ISBN 9781284057560.
- Harrison CN, Campbell PJ, Buck G, et al. (July 2005). "Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia". N. Engl. J. Med. 353 (1): 33–45. doi:10.1056/NEJMoa043800. PMID 16000354.
- Lanzkron S, Strouse JJ, Wilson R, et al. (June 2008). "Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease". Ann. Intern. Med. 148 (12): 939–55. doi:10.7326/0003-4819-148-12-200806170-00221. PMC . PMID 18458272.
- Sharma VK, Dutta B, Ramam M (2004). "Hydroxyurea as an alternative therapy for psoriasis". Indian J Dermatol Venereol Leprol. 70 (1): 13–7. PMID 17642550. Archived from the original on 2009-07-03.
- Rustin, MH (November 2012). "Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data". Br J Dermatol. 167 (Suppl 3): 3–11. doi:10.1111/j.1365-2133.2012.11208.x. PMID 23082810.
- Escribano, L.; Álvarez-Twose, I. N.; Sánchez-Muñoz, L.; Garcia-Montero, A.; Núñez, R.; Almeida, J.; Jara-Acevedo, M.; Teodósio, C.; et al. (2009). "Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients". Journal of Allergy and Clinical Immunology. 124 (3): 514–521. doi:10.1016/j.jaci.2009.05.003. PMID 19541349.
- Dalziel, K.; Round, A.; Stein, K.; Garside, R.; Price, A. (2004). "Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: A systematic review and economic analysis". Health technology assessment (Winchester, England). 8 (28): iii, ii1–120. PMID 15245690.
- Liebelt, E.; Balk, S.; Faber, W.; Fisher, J.; Hughes, C.; Lanzkron, S.; Lewis, K.; Marchetti, F.; Mehendale, H.; Rogers, J. M.; Shad, A. T.; Skalko, R. G.; Stanek, E. J. (2007). "NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea". Birth defects research. Part B, Developmental and reproductive toxicology. 80 (4): 259–366. doi:10.1002/bdrb.20123. PMID 17712860.
- Longe, Jacqueline L. (2002). Gale Encyclopedia Of Cancer: A Guide To Cancer And Its Treatments. Detroit: Thomson Gale. pp. 514–516. ISBN 978-1-4144-0362-5.
- Platt OS (2008). "Hydroxyurea for the treatment of sickle cell anemia". N. Engl. J. Med. 358 (13): 1362–9. doi:10.1056/NEJMct0708272. PMID 18367739.
- "hydroxyurea" at Dorland's Medical Dictionary
- Cokic VP, Smith RD, Beleslin-Cokic BB, et al. (2003). "Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase". J Clin Invest. 111 (2): 231–9. doi:10.1172/JCI16672. PMC . PMID 12531879. Archived from the original on 2009-01-15.
- Kettani, T; Gulbis, B; Ferster, A; Kumps, A (2009). "Plasma hydroxyurea determined by gas chromatography-mass spectrometry". Journal of Chromatography B. 877 (4): 446–450. doi:10.1016/j.jchromb.2008.12.048.
- Dresler WFC; Stein R (1869). "Ueber den Hydroxylharnstoff". Justus Liebigs Ann Chemie 150:1317–22.
- Rees C. David (2011). "The rationale for using hydroxycarbamide in the treatment of sickle cell disease". Haematologica. 96 (4): 488–491. doi:10.3324/haematol.2011.041988. PMC . PMID 21454878.
- Graham P.J. (1955). "Synthesis of Ureas". US Patent No. 2,705,727. E.I. du Pont de Nemours & Co., Wilmington, DE.
- Hussain KA, Abid DS, Adam GA (2016). "New Method for Synthesis of Hydroxyurea and Some of its Polymer Supported Derivatives As New Controlled Release Drugs". Journal of Basrah Research. 41 (1). doi:10.13140/RG.2.1.3607.2720.
- "Pharmacology and Biochemistry". PubChem. Archived from the original on 2017-05-18.
- Koç A, Wheeler LJ, Mathews CK, Merrill GF (January 2004). "Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools". J. Biol. Chem. 279 (1): 223–30. doi:10.1074/jbc.M303952200. PMID 14573610.
- Yarbro JW (1992). ""Mechanism of Action"". Seminars in Oncology. 19 (3): 1–10. PMID 1641648.